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Lung cancer is the leading cause of cancer mortality in most
countries, with the global incidence increasing by 0.5% per
year.1 The adrenal glands are common sites of metastases, as
evidenced by a series of 500 consecutive cancer necropsies,
where 42% of metastatic lung cancers involved the adrenal
glands.  This high prevalence of adrenal metastases may reflect
the rich sinusoidal blood supply and high local concentration
of glucocorticoids, which may promote implantation of
metastases.2
Overt hypoadrenalism is uncommon in patients with stage 3
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Introduction. Lung cancer is the leading cause of cancer
mortality in most countries. The adrenal glands are common
sites of metastatic lung cancer as approximately 40% of
subjects with stage 4 bronchogenic carcinoma have adrenal
metastases. The prevalence of biochemical hypoadrenalism is,
however, remarkably poorly documented. 
Objectives. Our study aimed to determine the prevalence of
primary hypoadrenalism, as defined by a subnormal cortisol
response to the 250 µg adrenocorticotrophic hormone (ACTH)
stimulation test, in patients with stage 3 and 4 lung cancer.
Methods. Thirty patients with stage 3 and 4 bronchogenic
carcinoma were prospectively recruited from the bronchus
clinic. Demographic data and electrolytes were recorded and
each patient had a 250 µg ACTH stimulation test to determine
the prevalence of overt adrenal insufficiency, defined as a +30
minute cortisol of less than 550 nmol/l.
Results. The median age and quartile deviation was 62 (10)
years and the median basal cortisol was 429.5 (321) nmol/l.
The median peak cortisol was 828.5 (342) nmol/l (range 
536 - 1 675 nmol/l). Twenty-eight patients (93.3%) had an
appropriate rise of cortisol to greater than 550 nmol/l
following 250 µg ACTH stimulation. Two patients (6.7%) had
mild primary adrenal failure with a peak cortisol between 500
and 550 nmol/l associated with a raised plasma ACTH
concentration (131.4 and 10.5 pmol/l, normal 2.2 - 10 pmol/l).
Twenty-eight patients (92.9%) were normonatraemic, while
the two hyponatraemic patients had biochemical evidence of
the syndrome of inappropriate antidiuretic hormone
secretion. 
Conclusion. In conclusion, despite evidence that the adrenal
glands of patients with disseminated bronchogenic carcinoma
are frequently affected by metastatic disease, biochemical
evidence of clinically significant hypoadrenalism is relatively
uncommon and is not accurately predicted by electrolyte
abnormalities. 
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Despite the plethora of reports confirming the high
frequency of adrenal metastases in patients with bronchogenic
carcinoma, the prevalence of hypoadrenalism is remarkably
poorly documented. One may speculate that hypoadrenalism
may be uncommon as the adrenal glands possess large
functional reserve, since 90% of both adrenal cortices must be
replaced by tumour before adrenocortical insufficiency
develops.3-5 There are, however, several factors that may
potentially account for underreporting of hypoadrenalism
associated with metastatic carcinoma. Firstly, since the
symptoms of adrenal insufficiency are similar to those of
extensive metastatic disease, adrenal insufficiency is seldom
considered in a patient whose condition is progressively
deteriorating with increasing anorexia, malaise and weight
loss.6 Secondly, the treatment of metastatic cancer of the lung
with corticosteroids may mask the state of adrenal
insufficiency.7 Finally, since the syndrome of inappropriate
antidiuretic hormone (SIADH) is often encountered in small-
cell carcinoma, hyponatraemia may be incorrectly attributed to
SIADH rather than primary adrenal insufficiency.7
In 1855 Addison8 first suggested that adrenal metastases
could induce adrenal insufficiency. Several isolated cases
supporting this contention have subsequently been reported.9,10
In addition, there have been reports of adrenal insufficiency as
the sole manifestation of cancer and of malignancies initially
presenting as an Addisonian crisis.11,12 There are only two
prospective studies examining the prevalence of
hypoadrenalism in metastatic bronchogenic carcinoma.
Redman and colleagues13 reported a 33% prevalence of
hypoadrenalism in an early study of 15 patients with a variety
of metastatic carcinomas and bilateral adrenal enlargement on
CT scan. However, the criteria for hypoadrenalism used in this
paper (cortisol increment < 150 nmol/l or a peak cortisol
concentration < 415 nmol/l) do not accord with validated
criteria for primary adrenal insufficiency.14,15 Lutz and
colleagues16 employed more conventional diagnostic criteria
and studied patients with either unilateral (N = 8) or bilateral
(N = 9) adrenal metastases. In this group selected for the
presence of adrenal metastases there was no evidence of overt
hypoadrenalism. We were interested to determine the
prevalence of primary hypoadrenalism prospectively in
patients with advanced bronchogenic carcinoma not pre-
selected for the presence of adrenal metastases. We therefore
designed a prospective study of patients with advanced
bronchogenic carcinoma with the following objective, namely
to determine the prevalence of primary hypoadrenalism in
patients with stage 3 and 4 lung cancer, using validated
criteria.
Materials and methods
Thirty patients were recruited prospectively from the combined
bronchus clinic at Groote Schuur Hospital, Cape Town.
Patients were considered eligible for the study if they had
histological or cytological proof of primary lung carcinoma
with stage 3 or 4 (non-small-cell carcinoma) or advanced
disease (small-cell carcinoma) according to the 1997
international TNM (tumour, node, metastasis) staging system
for lung cancer.17 Patients were considered to have metastatic
disease if one or more of the following conditions were met:
pathological fractures or radiological bony erosions, ultrasound
or CT evidence of hepatic metastases, contralateral lung
involvement, cutaneous involvement proved by biopsy, CT
evidence of brain metastases or extension into pleura,
pericardium, diaphragm or mediastinal nodes. Patients were
excluded if they had had oral glucocorticoid treatment within
the previous 6 months or if the subjects were on therapy that
could influence cortisol metabolism, e.g. rifampicin. All
patients provided written informed consent and the study was
approved by the Research Ethics Committee of the University
of Cape Town Medical School.  
The nature of metastatic disease, height, weight and body
mass index were recorded. Hyperpigmentation and postural
hypotension were noted (a fall in systolic blood pressure > 20
mmHg and/or a fall in diastolic blood pressure > 10 mmHg
after standing for 3 minutes) and serum, urinary electrolytes
and osmolality were measured. SIADH was suggested by the
combination of hyponatraemia (Na+ < 130 mmol/l) with low
plasma osmolality (< 280 mOsm/kg), inappropriately high
urine osmolality and urinary sodium > 20 mmol/l, in the
absence of clinical volume depletion or biochemical evidence of
hypothyroidism, hypoadrenalism or renal impairment. A
standard intravenous 250 µg adrenocorticotrophic hormone
(ACTH) test (tetracosactide) was performed and patients were
defined as having overt primary hypoadrenalism if the 30-
minute cortisol was < 550 nmol/l with increased basal plasma
ACTH (normal 2.2 - 10 pmol/l).18 Compensated
hypoadrenalism was defined as a ratio of ACTH/cortisol
(pmol/l:nmol/l) > 0.028.19 Cortisol was measured using the
Automated Chemiluminescence System, Cheiron ACS 180
(Beyer Corporation, New York 10591-509).  The inter- and intra-
assay coefficient of variation was 6.4 - 9.7%.  ACTH assay was
performed using the Immulite 2000 chemiluminescent
immunoassay system and the inter- and intra-assay of
coefficient of variation was 6.3 - 8%.  Results are expressed as
medians and quartile deviation (QD).  Since sample sizes were
small and variances were generally not homogeneous the
Mann-Whitney test was employed for all the comparisons.
Results
Baseline demographic data
Baseline demographic data are summarised in Table I. The
mean ± standard deviation (SD) age was 60.9 ± 9.45 years.
Seven patients had proven advanced small-cell carcinoma,
whereas 23 patients had non-small-cell carcinoma, of whom 14
had stage 3 (61%) and 9 stage 4 disease (39%). 
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Basal cortisol and ACTH
The basal cortisol ranged from 129 to 978 nmol/l in both
groups combined, while the median basal cortisol was 432
nmol/l (QD 473) for the non-small-cell carcinoma group and
212 nmol/l (QD 505) for the small-cell carcinoma group 
(p > 0.05). The median basal ACTH was 2.8 pmol/l (QD 2.2) for
the non-small-cell carcinoma group and 6.35 pmol/l (QD 9.75)
for the small-cell group (p > 0.05). Four patients (13.3%) had an
abnormally elevated plasma ACTH concentration. 
Cortisol response to 250 µg ACTH stimulation 
(Fig. 1)
The overall median peak serum cortisol 30 minutes after 
250 µg ACTH stimulation was 828.5 nmol/l (QD 345), range
536 - 1 675 nmol/l. When comparing the two histological
subgroups, the median peak serum cortisol was 832 nmol/l
(QD 336) for the non-small-cell carcinoma group and 792
nmol/l (QD 563) for the small-cell carcinoma group (p = 0.86).
There was a close correlation between basal and 30-minute
cortisol (r = 0.78, p < 0.0005), while the correlation between
basal and incremental cortisol was poor ( r = –0.07, p = 0.9). 
Twenty-eight patients (93.3%) had an appropriate rise of
cortisol to greater than 550 nmol/l following 250 µg ACTH
stimulation. Two patients (6.7%) had definite evidence of
adrenal insufficiency, with a peak cortisol of 536 and 545
nmol/l associated with a raised plasma ACTH concentration of
131.4 and 10.5 pmol/l respectively (normal 2.2 - 10 pmol/l).
The overall prevalence of adrenal insufficiency was therefore
6.7% in our series (95% confidence interval (CI): 0.8% - 22.1%).
Two further subjects had an elevated basal ACTH
concentration of 58.9 and 13.4 pmol/l (normal 2.2 - 10 pmol/l)
and their peak cortisol levels following ACTH stimulation were
997 and 762 nmol/l respectively.  In order to ascertain whether
these two subjects had compensated hypoadrenalism we
determined the ACTH-to-cortisol ratio, which was 0.059 and
0.017 respectively (ratio > 0.028 suggests compensated
hypoadrenalism).16 Thus we found an additional patient who
had compensated hypoadrenalism (ACTH-to-cortisol ratio
0.059), bringing the overall prevalence of hypoadrenalism in
our study to 10%.
Clinical and biochemical predictors of
hypoadrenalism
Clinical evidence of hyperpigmentation was not predictive of
hypoadrenalism since none of the 23.3% of the patients with
hyperpigmentation had a subnormal serum cortisol response to
ACTH stimulation. Similarly, postural hypotension was of
limited utility since 13.3% of patients had postural hypotension
and only 1 of these subjects had compensated hypoadrenalism.
Twenty-eight patients (93.3%), including the 2 with adrenal
insufficiency, were normonatraemic, while the 2 hyponatraemic
patients (6.7%) had biochemical evidence of SIADH.  All
patients were normokalaemic and the 2 patients with
hypercalcaemia (6.7%) had normal adrenal function, suggesting
that the hypercalcaemia was related to the underlying
malignancy rather than to cortisol deficiency.  Despite
convincing evidence in the literature that a basal 08h00 cortisol
of less than 100 nmol/l reliably predicts hypoadrenalism, this
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Table I. Baseline demographic data*
Small-cell Non-small-
carcinoma cell carcinoma
(N = 7) (N = 23)
Age (yrs) 63.29 (7.11) 60.13 (10.07)
Sex (M:F) 4:3 17:6
BMI 23.32 (1.94) 24.58 (5.09)
Albumin 38.57 (3.46) 35.36 (5.30)
N (%) with › Ca++ 1 (14.3) 1 (4.3)
N (%) with flNa+ 2 (28.6) 2 (8.7)
N (%) with › K+ 0 3 (13.0)
* Data expressed as mean (SD) unless otherwise indicated.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Basal and 30-minute plasma cortisol concentrations following
250 µg ACTH stimulation. The horizontal line at 550 nmol/l
indicates the minimum cortisol value that defines a normal +30
minute response to ACTH stimulation.
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cutoff was of limited clinical utility in our study where the
subjects with both mild and compensated adrenal failure had
basal cortisol levels ranging from 129 nmol/l to 815 nmol/l.14
Discussion
Despite the fact that the adrenal glands are common sites of
metastatic spread in patients with bronchogenic carcinoma, our
study suggests that clinically relevant hypoadrenalism is
distinctly uncommon.  However, 2 patients had adrenal
insufficiency, with a peak cortisol of between 500 and 550
nmol/l was associated with a raised plasma ACTH
concentration.  It is relevant to note that these patients had no
associated clinical or biochemical features of hypoadrenalism
and were not considered to warrant glucorticoid
supplementation.  In addition 2 further patients with an
elevated basal plasma ACTH of 58.9 and 13.9 pmol/l
responded to stimulation with 250 µg ACTH, with a normal
cortisol response of 997 and 762 nmol/l. These patients may be
considered to have compensated primary adrenal insufficiency
and although they would be at increased risk of developing
overt primary adrenal insufficiency in the future, there would
currently be no benefit in glucocorticoid supplementation. 
The 250 µg dose of ACTH used in this study results in
markedly supraphysiological concentrations of ACTH, which
could potentially limit the ability of the test to detect subtle
degrees of cortisol deficiency (false-negative test). The low-
dose 1 µg ACTH stimulation test has therefore recently been
advocated as a more sensitive test for hypoadrenalism,
particularly in the setting of suspected ACTH deficiency. Early
enthusiasm for the sensitivity of the 1 µg ACTH stimulation
test in the evaluation of patients with pituitary disease has,
however, been dampened by several reports indicating that in
the setting of partial ACTH deficiency, the low-dose test may,
like the standard 250 µg test, produce false-negative results.20
In the single report exploring the utility of the 1 µg ACTH
stimulation test for the diagnosis of primary hypoadrenalism in
patients with pre-clinical hypoadrenalism and positive adrenal
antibodies there was full concordance between the results of
the 250 µg and 1 µg tests, indicating no diagnostic advantage
for the low-dose test.21 This limited sensitivity probably relates
to the attainment of supraphysiological concentrations of
ACTH following administration of both the 250 µg (60 000
ng/l) and 1 µg (> 100 ng/l) ACTH doses, concentrations which
are substantially higher than the plasma ACTH concentration
that elicits a maximal cortisol response (70 - 80 ng/l).22 In light
of these data we decided to use the conventional 250 µg ACTH
stimulation test for the evaluation of hypoadrenalism in our
patient cohort.  A crucial characteristic of our patient cohort
was that none of our patients was acutely unwell at the time of
being evaluated.
The relatively low prevalence of hypoadrenalism reported in
this study contrasts sharply with previous studies reporting
that more than 40% of patients with metastatic bronchogenic
carcinoma have adrenal metastases at necropsy.23 This
discrepancy between frequent pathological adrenal
involvement and infrequent biochemical hypoadrenalism is
well documented and attests to the remarkable functional
reserve of the adrenal glands.3,4 In light of our findings it is
important to evaluate earlier studies of hypoadrenalism in
patients with metastatic bronchogenic carcinoma critically. In a
study of only 15 patients with metastatic carcinoma and
bilateral adrenal enlargement on CT scan Redman and
colleagues13 reported a 33% prevalence of hypoadrenalism.
However, the criteria used to define hypoadrenalism in this
study, namely failure to increase serum cortisol by at least 
150 nmol/l and/or a peak cortisol of less than 415 nmol/l
following 250 µg ACTH stimulation, are arbitrary and do not
accord with any accepted diagnostic criteria for
hypoadrenalism.14,15 Consensus is now emerging that
calculation of the increment in serum cortisol is of limited
value in the assessment of the adrenocortical function, as a
maximally stressed patient with an intact adrenal axis may
have a blunted cortisol response to exogenous ACTH. 24 If one
re-examines the study by Redman et al.13 employing validated
criteria, namely a peak cortisol response to ACTH of less than
550 nmol/l, then the prevalence of hypoadrenalism is reduced
to 20%.  Arecent study by Lutz and colleagues16 examined
adrenocortical function in patients with either unilateral 
(N = 8) or bilateral (N = 9) macrometastases of the adrenal
gland.  Interestingly, no patient had overt adrenal insufficiency
(defined as a serum cortisol response to ACTH stimulation
below 560 nmol/l, while only 2 of 9 patients (22%) with
bilateral macrometastases had subclinical hypoadrenalism
(defined as an elevated basal ACTH/cortisol ratio). 16 The
reported prevalence of overt hypoadrenalism of 20 - 22% from
studies that selected patients for the presence of adrenal
metastases is in accordance with our study, which documented
a combined prevalence of hypoadrenalism (overt and
compensated) of 10% in a group of patients with advanced
bronchogenic carcinoma who were not selected for CT
evidence of adrenal metastases.
The predictive value of clinical and biochemical markers of
hypoadrenalism in our study was poor since none of the
patients considered to have hyperpigmentation had
biochemical hypoadrenalism.  Conversely, the 2 patients with
mild adrenal insufficiency and elevated plasma ACTH
concentration were not hyperpigmented.  We propose that
hyperpigmentation reflects longstanding ACTH excess which
is not typically a feature in patients with adrenal metastases.
Similarly, there was no correlation between postural
hypotension and hypoadrenalism.  Although hyponatraemia
and hyperkalaemia had a prevalence of 78% and 52%
respectively in our previous series of 50 patients with
Addison’s disease, neither of the 2 patients with mild
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hypoadrenalism in this study had any electrolyte disturbance.25
This likely reflects the mild cortisol deficiency with
preservation of mineralocorticoid function in this group of
patients.  Finally, basal cortisol cannot be used as a predictor
for overt or compensated hypoadrenalism.
There are several potential criticisms of our study. Firstly the
limited number of enrolled subjects may have resulted in a
falsely low prevalence of hypoadrenalism. This uncertainty is
reflected in the wide CIs for the prevalence of overt
hypoadrenalism of 0.8 - 22.1% and can only be addressed by
increasing the number of patients recruited in future studies. In
addition, although the patients had advanced bronchogenic
carcinoma according to conventional staging, serum albumin
and body mass index were remarkably well preserved (Table I). It
is therefore possible that patients with clinically more
advanced bronchogenic carcinoma would have a higher
prevalence of primary hypoadrenalism.  Finally, patients were
not selected for the presence of adrenal metastases on CT
imaging as in previous studies. We were, however, interested
in answering a clinically relevant question, namely the
prevalence of hypoadrenalism in unselected patients with
advanced bronchogenic carcinoma as this is the problem
frequently faced by clinicians, who typically do not have CT
data available when assessing a patient with advanced
malignancy and possible hypoadrenalism. It would, however,
have been interesting to verify the presence of adrenal
metastases in our small group of patients with overt and
compensated adrenal failure. 
In conclusion, despite frequent pathological adrenal
involvement in patients with metastatic bronchogenic
carcinoma, clinically relevant hypoadrenalism is distinctly
uncommon. Furthermore, electrolyte disturbances and basal
cortisol concentration are of limited use in identifying the
occasional patient with mild hypoadrenalism.
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